SCHEDULE 13G/A: Armistice Capital Discloses 4.99% Passive Stake in 60 Degrees Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc. as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 77,357 shares of Common Stock in 60 Degrees Pharmaceuticals, Inc.
• This ownership represents 4.99% of the company's outstanding Common Stock.
• Armistice Capital, LLC, an investment adviser, and Steven Boyd, its managing member, share voting and dispositive power over these shares.
• The shares are held by Armistice Capital Master Fund Ltd., an investment advisory client of Armistice Capital, LLC.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a passive investment purpose and no intent to influence control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly sway sentiment positively or negatively. It indicates a passive investment.

Positives

• The disclosure of an institutional investor, Armistice Capital, holding a significant stake (4.99%) in 60 Degrees Pharmaceuticals may signal confidence in the company's prospects.
• The filing confirms that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer, which suggests a stable, long-term passive investment.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

This filing reflects a common practice in the investment industry where institutional investors disclose their passive ownership stakes in publicly traded companies. For pharmaceutical companies like 60 Degrees Pharmaceuticals, attracting institutional investment can be a sign of market interest in their pipeline or business model, although a 13G indicates a passive, non-influential position.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, potentially influencing investor confidence or perception of the stock's liquidity.

Key Dates

Keywords

Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Armistice Capital, 60 Degrees Pharmaceuticals, Common Stock, Investment Management, Passive Investment